{"filing":{"accession_number":"0001193125-26-304880","cik":"0001341235","ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"aldx-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526304880/aldx-20260714.htm"},"events":[{"id":18192,"run_id":16344,"accession_number":"0001193125-26-304880","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aldeyra disclosed receipt of FDA meeting minutes regarding potential resubmission of a New Drug Application (NDA) for reproxalap and plans to request a Type D meeting with the FDA by Q3 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. The disclosure centers on an operational/regulatory development rather than a financial or governance event.","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16927,"accession_number":"0001193125-26-304880","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aldeyra disclosed receipt of FDA meeting minutes regarding potential resubmission of a New Drug Application (NDA) for reproxalap and plans to request a Type D meeting with the FDA by Q3 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. The disclosure centers on an operational/regulatory development rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:47:36.802676+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16927,"accession_number":"0001193125-26-304880","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aldeyra disclosed receipt of FDA meeting minutes regarding potential resubmission of a New Drug Application (NDA) for reproxalap and plans to request a Type D meeting with the FDA by Q3 2026. This is a material regulatory milestone in the drug development process that would affect investor assessment of the company's pipeline progress, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. The disclosure centers on an operational/regulatory development rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:47:36.802676+00:00","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-07-15"}]}